RxDoctor Payments DataLook up a doctor →

Ferris George, MD

Cardiovascular Disease · St Augustine, FLNPI 1467474080

Payments from drug & device makers

$3,768,782in general payments, 2019–2025

Across 1,062 payments — averaging $3548.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2.4M
  • Boehringer Ingelheim International GmbH$318K
  • Boehringer Ingelheim$311K
  • Merck$156K
  • Bayer$115K
  • AstraZeneca$114K
  • plus $354K from 33 others

What the payments were for

  • Travel & lodging$1,2388%
  • Food & beverage$14,41790%
  • Education$4203%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,768,782 in reported general payments places this provider in the 95th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$338,601
Medicare patients
987
Services billed
3,920

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban600$590,793
Repatha SureclickEvolocumab242$170,538
EntrestoSacubitril/Valsartan125$137,587
FarxigaDapagliflozin Propanediol61$54,340
XareltoRivaroxaban43$53,437
Praluent PenAlirocumab32$30,793
MultaqDronedarone Hcl22$18,789
BrilintaTicagrelor19$16,712
Repatha SyringeEvolocumab19$13,888
Metoprolol Succinate713$9,017
Rosuvastatin Calcium676$8,360
Atorvastatin Calcium561$5,083
ClopidogrelClopidogrel Bisulfate440$4,594
Losartan Potassium367$3,200
Ezetimibe153$2,830

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$384$590,793600 claims
NovartisEntresto$2,400,537$137,587125 claims
AstraZenecaFarxiga, Brilinta$113,934$71,05280 claims
Johnson & JohnsonXarelto$217$53,43743 claims
Sanofi-aventis U.S. LLCMultaq$152$18,78922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in St Augustine

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →